AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22860302 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 13
Study 19545320 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions associated with the home use of a disclosing agent (1% neutral red)
Number of subjects: 32
Study 19545320 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral and denture hygiene instructions
Number of subjects: 32
Study 19545320 — intervention group
Group type: COMPARATOR
Intervention: Follow‐up only (control)
Number of subjects: 32
Study 18467544 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrient supplement (protein, carbohydrate, calcium, and vitamin D)
Number of subjects: 0
Study 18467544 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 15690254 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based moderated case discussions delivered via e-mail
Number of subjects: 58
Study 15690254 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 58
Study 12633127 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated family and individual therapy (IFIT)
Number of subjects: 30
Study 12633127 — intervention group
Group type: COMPARATOR
Intervention: Standard community care (CM)
Number of subjects: 30
Study 12892048 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (1600 IU/d)
Number of subjects: 158
Study 12892048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 8550792 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 2 IU/m2
Number of subjects: 12
Study 8550792 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-like Growth Factor I (IGF‐I) 80 micrograms/kg
Number of subjects: 12
Study 1801154 — intervention group
Group type: EXPERIMENTAL
Intervention: Amocarzine 3 mg/kg oral dose twice daily for three days (fed patients)
Number of subjects: 20
Study 1801154 — intervention group
Group type: COMPARATOR
Intervention: Amocarzine 3 mg/kg oral dose twice daily for three days (fasting patients)
Number of subjects: 20
Study 6861446 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 9
Study 6861446 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 9
Study 6861446 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 9
Study 6861446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30796027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylation of cg08309687 (LINC00649)
Number of subjects: 4525
Study 30796027 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 CpGs associated with hepatic fat in EA participants
Number of subjects: 4525
Study 29874535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment (200 mg orally) followed by misoprostol (800 μg vaginally)
Number of subjects: 300
Study 29874535 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone (800 μg vaginally)
Number of subjects: 300
Study 29874535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone pretreatment
Number of subjects: 300
Study 29874535 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol alone
Number of subjects: 300
Study 27095698 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA group; n=20) plus standard care
Number of subjects: 38
Study 27095698 — intervention group
Group type: COMPARATOR
Intervention: Standard care only (control group, n=18)
Number of subjects: 38
Study 24767003 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (4ug/kg)
Number of subjects: 62
Study 24767003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 22647753 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetic individuals
Number of subjects: 1372
Study 22647753 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of diabetes, blood pressure, waist, high-density lipoprotein cholesterol, and FPG
Number of subjects: 1372
Study 22647753 — intervention group
Group type: EXPERIMENTAL
Intervention: Family history of premature CVD, waist, and FPG
Number of subjects: 1372
Study 20231764 — intervention group
Group type: EXPERIMENTAL
Intervention: Respondents to the initial mailed screener
Number of subjects: 1049
Study 20231764 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible individuals
Number of subjects: 1049
Study 20231764 — intervention group
Group type: EXPERIMENTAL
Intervention: Enrolled individuals
Number of subjects: 1049
Study 17385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone (HC)
Number of subjects: 5
Study 17385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (DEX)
Number of subjects: 5
Study 17385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MPL)
Number of subjects: 5
Study 17385022 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (PNL)
Number of subjects: 5
Study 17385022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 16351362 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright face orientation
Number of subjects: 0
Study 16351362 — intervention group
Group type: EXPERIMENTAL
Intervention: Inverted face orientation
Number of subjects: 0
Study 16351362 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrelevant faces
Number of subjects: 0
Study 16351362 — intervention group
Group type: EXPERIMENTAL
Intervention: Semantic processing goal
Number of subjects: 0
Study 11867508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored psycho-educational intervention
Number of subjects: 742
Study 11867508 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 742
Study 10215706 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 200/0.5
Number of subjects: 50
Study 10215706 — intervention group
Group type: COMPARATOR
Intervention: 5% albumin
Number of subjects: 50
Study 8537922 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing artificial tooth materials (Group 1)
Number of subjects: 67
Study 8537922 — intervention group
Group type: EXPERIMENTAL
Intervention: New experimental material (Group 2)
Number of subjects: 67
Study 8537922 — intervention group
Group type: COMPARATOR
Intervention: Bioform IPN resin teeth (Group 3)
Number of subjects: 67
Study 1284163 — intervention group
Group type: EXPERIMENTAL
Intervention: gallopamil SR 100 mg twice a day
Number of subjects: 118
Study 1284163 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 118
Study 6142717 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oral solution of bromazepam (3 mg)
Number of subjects: 6
Study 6142717 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid oral solution of bromazepam (1.5 mg)
Number of subjects: 6
Study 31540613 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for cocaine use disorders (CUD)
Number of subjects: 629
Study 30088834 — intervention group
Group type: EXPERIMENTAL
Intervention: MBCT + TAU
Number of subjects: 106
Study 27184297 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Bias Modification Therapy (ABMT)
Number of subjects: 37
Study 27184297 — intervention group
Group type: COMPARATOR
Intervention: Control Therapy
Number of subjects: 37
Study 25348259 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepping Stones Triple P (SSTP)
Number of subjects: 209
Study 25348259 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 209
Study 23103033 — intervention group
Group type: EXPERIMENTAL
Intervention: MGuard stent
Number of subjects: 433
Study 23103033 — intervention group
Group type: COMPARATOR
Intervention: Control stents (bare metal or drug-eluting)
Number of subjects: 433
Study 20840318 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 15 mg
Number of subjects: 312
Study 20840318 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 10 mg
Number of subjects: 312
Study 20840318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 312
Study 17880872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional autologous blood injection
Number of subjects: 64
Study 17880872 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 64
Study 16115973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl injection over 2 seconds
Number of subjects: 450
Study 16115973 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl injection over 15 seconds
Number of subjects: 450
Study 16115973 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl injection over 30 seconds
Number of subjects: 450
Study 16115973 — intervention group
Group type: EXPERIMENTAL
Intervention: Light smoking (<10 cigarettes per day)
Number of subjects: 450
Study 12107308 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-portal endoscopic carpal tunnel release
Number of subjects: 147
Study 12107308 — intervention group
Group type: COMPARATOR
Intervention: Open carpal tunnel release
Number of subjects: 147
Study 9144753 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, behaviorally based counseling by physicians, plus a telephone follow‐up 2 weeks later
Number of subjects: 255
Study 9144753 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 255
Study 7957497 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 U kg‐1 body weight twice weekly during a 3 week period)
Number of subjects: 62
Study 7957497 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rhEPO)
Number of subjects: 62
Study 3669729 — intervention group
Group type: EXPERIMENTAL
Intervention: MgSO4 inhalation
Number of subjects: 16
Study 3669729 — intervention group
Group type: COMPARATOR
Intervention: NaCl (saline)
Number of subjects: 16
Study 31960624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 35 mg
Number of subjects: 24
Study 31960624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 105 mg
Number of subjects: 24
Study 31960624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab 280 mg
Number of subjects: 24
Study 31960624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31960624 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (all doses)
Number of subjects: 24
Study 30126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-level components of the physical HIV risk environment in Ciudad Juarez
Number of subjects: 584
Study 30126411 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-level components of the physical HIV risk environment in Tijuana
Number of subjects: 584
Study 27765357 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecithin-formulated Boswellia extract (CSP)
Number of subjects: 12
Study 27765357 — intervention group
Group type: COMPARATOR
Intervention: Non-formulated Boswellia extract (BE)
Number of subjects: 12
Study 23825183 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 230
Study 23825183 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 230
Study 22538140 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care video messages from diabetes nurse practitioner
Number of subjects: 65
Study 22538140 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care video messages from diabetes nurse practitioner (viewed >10 a month)
Number of subjects: 65
Study 22538140 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 65
Study 20864916 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6 (oxaliplatin 85 mg/m², leucovorin 350 mg, and 5-fluorouracil 400 mg/m² bolus; 2.4 g/m² infusion, 46 h) day 1; bevacizumab 5 mg/kg on day 1; cetuximab 400 mg/m² on day 1, then 250 mg/m² on days 1 and 8, every 14 days until progressive disease (PD)
Number of subjects: 31
Study 18311567 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric ablation profiles developed based on individual wavefront data and standardized correction profiles.
Number of subjects: 0
Study 18311567 — intervention group
Group type: COMPARATOR
Intervention: Conventional spheric ablation profiles.
Number of subjects: 0
Study 14644790 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal counseling session and signed contract promising to wear bicycle helmets; helmet fitting for 57 children who did not own helmets
Number of subjects: 222
Study 14644790 — intervention group
Group type: COMPARATOR
Intervention: Control group received a photocopied photograph of the hospital
Number of subjects: 222
Study 11775238 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor (rbFGF) 150 AU/cm2/day
Number of subjects: 1024
Study 11775238 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle without rbFGF)
Number of subjects: 1024
Study 11775238 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant bovine basic fibroblast growth factor (rbFGF)
Number of subjects: 1024
Study 11775238 — intervention group
Group type: COMPARATOR
Intervention: Control (the patients themselves)
Number of subjects: 1024
Study 8977914 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbasalate (equivalent to aspirin 325 mg daily, single dose 6 hours post-operation, repeated for 7 days)
Number of subjects: 56
Study 8977914 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbasalate
Number of subjects: 56
Study 8977914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 8977914 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbasalate and Placebo
Number of subjects: 56
Study 1587379 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms 17 beta-estradiol (Vagifem) administered as a vaginal tablet, treated once daily for 2 weeks and twice a week for 10 weeks
Number of subjects: 164
Study 1587379 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms 17 beta-estradiol (Vagifem)
Number of subjects: 164
Study 1587379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study 4025944 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated Partial Thromboplastin Time (APTT)
Number of subjects: 0
Study 4025944 — intervention group
Group type: EXPERIMENTAL
Intervention: Howel Time (HT)
Number of subjects: 0
Study 4025944 — intervention group
Group type: COMPARATOR
Intervention: Both APTT and HT
Number of subjects: 0
Study 31645444 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenovirus Type 5-Based HIV-1 Vaccines
Number of subjects: 0
Study 29517132 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD5718
Number of subjects: 0
Study 29517132 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26881270 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of infants' problems
Number of subjects: 70
Study 26881270 — intervention group
Group type: EXPERIMENTAL
Intervention: Carer's level of concern
Number of subjects: 70
Study 26881270 — intervention group
Group type: EXPERIMENTAL
Intervention: Child's engagement in cognitive tasks
Number of subjects: 70
Study 26881270 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic assessment
Number of subjects: 70
Study 24059649 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (10 g/d for 8 weeks)
Number of subjects: 49
Study 24059649 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (control group)
Number of subjects: 49
Study 22291886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg orally
Number of subjects: 0
Study 22291886 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg orally
Number of subjects: 0
Study 22291886 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0 µg (placebo)
Number of subjects: 0
Study 20502388 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-positive adolescents scoring at or above the clinical cutoff on the ADI (n = 45)
Number of subjects: 177
Study 20502388 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-positive adolescents scoring below the clinical cutoff on the ADI (n = 68)
Number of subjects: 177
Study 20502388 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-negative adolescents (n = 64)
Number of subjects: 177
Study 18349316 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation stent group (self-expandable esophageal stent loaded with 125I seeds)
Number of subjects: 53
Study 18349316 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional self-expandable covered stent)
Number of subjects: 53
Study 16362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal desmopressin 1x 20 microg for 2 months
Number of subjects: 55
Study 16362593 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditioning therapy for 2 months
Number of subjects: 55
Study 16362593 — intervention group
Group type: COMPARATOR
Intervention: Intranasal isotonic solutions (placebo)
Number of subjects: 55
Study 12358166 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled RF
Number of subjects: 59
Study 12358166 — intervention group
Group type: COMPARATOR
Intervention: Standard RF
Number of subjects: 59
Study 10073511 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg mifepristone
Number of subjects: 1717
Study 10073511 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone
Number of subjects: 1717
Study 10073511 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 1717
Study 10073511 — intervention group
Group type: EXPERIMENTAL
Intervention: mifepristone (all doses)
Number of subjects: 1717
Study 7579847 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde warm blood cardioplegia
Number of subjects: 0
Study 7579847 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade warm blood cardioplegia
Number of subjects: 0
Study 7579847 — intervention group
Group type: COMPARATOR
Intervention: Cold oxygenated crystalloid cardioplegia
Number of subjects: 0
Study 7579847 — intervention group
Group type: COMPARATOR
Intervention: Antegrade cold blood cardioplegia
Number of subjects: 0
Study 2149565 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone hydrochloride (average dose 201 mg)
Number of subjects: 42
Study 2149565 — intervention group
Group type: COMPARATOR
Intervention: Placebo (average dose 238 mg)
Number of subjects: 42
Study 484765 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 616
Study 484765 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 616
Study 31423117 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Sign-On (SSO) implementation
Number of subjects: 19
Study 28724652 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission bradycardia (AHR <60 beats per minute)
Number of subjects: 1460
Study 28724652 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission tachycardia (AHR >100 beats per minute)
Number of subjects: 1460
Study 24990200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg once-daily tadalafil
Number of subjects: 144
Study 24990200 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-mg alternate-day tadalafil
Number of subjects: 144
Study 24640150 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberin
Number of subjects: 257
Study 24640150 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapeutics alone
Number of subjects: 257
Study 21078200 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED‐IT Resources (provision of materials including DVD, handbooks, pedometer, tape measure)
Number of subjects: 159
Study 21078200 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED‐IT Online (same materials as SHED‐IT Resources plus access to and instruction on how to use the study website)
Number of subjects: 159
Study 21078200 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control
Number of subjects: 159
Study 18251638 — intervention group
Group type: COMPARATOR
Intervention: Toothbrush alone
Number of subjects: 25
Study 18251638 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush + unwaxed floss
Number of subjects: 25
Study 18251638 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush + woven floss
Number of subjects: 25
Study 18251638 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush + shred-resistant floss
Number of subjects: 25
Study 18251638 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush + powered flosser
Number of subjects: 25
Study 16830130 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 0 mg with alcohol
Number of subjects: 18
Study 16830130 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 75 mg
Number of subjects: 18
Study 16830130 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 18
Study 16830130 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 18
Study 16830130 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA with alcohol
Number of subjects: 18
Study 14550442 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet low in fat and high in fiber, fruits, and vegetables
Number of subjects: 1197
Study 14550442 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1197
Study 10997956 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (1.0 g CHO.kg body mass(‐1) prior to and 0.5 g CHO.kg body mass(‐1) every 10 minutes during IRT)
Number of subjects: 8
Study 9116176 — intervention group
Group type: EXPERIMENTAL
Intervention: CDR Cognitive Assessment System
Number of subjects: 45
Study 9116176 — intervention group
Group type: EXPERIMENTAL
Intervention: RBAD
Number of subjects: 45
Study 9116176 — intervention group
Group type: COMPARATOR
Intervention: Mattis Dementia Rating Scale
Number of subjects: 45
Study 9116176 — intervention group
Group type: COMPARATOR
Intervention: Mini‐Mental State Examination
Number of subjects: 45
Study 9116176 — intervention group
Group type: COMPARATOR
Intervention: Wechsler Memory Scale‐Revised
Number of subjects: 45
Study 9116176 — intervention group
Group type: COMPARATOR
Intervention: Alzheimer's Disease Assessment Scale‐Cognitive Subscale
Number of subjects: 45
Study 9116176 — intervention group
Group type: COMPARATOR
Intervention: Repeatable Battery for the Assessment of Dementia (RBAD)
Number of subjects: 45
Study 2002211 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.15 mg/kg
Number of subjects: 0
Study 2002211 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0
Study 2002211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0